KNTE Key Statistics, Chart & Performance
The current stock price of KNTE is 2.65 USD. In the past month the price increased by 2.32%. In the past year, price decreased by -56.63%.
KNTE Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to KNTE. When comparing the yearly performance of all stocks, KNTE is a bad performer in the overall market: 86.11% of all stocks are doing better.
KNTE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to KNTE. KNTE has a great financial health rating, but its profitability evaluates not so good.
KNTE Financial Highlights
Over the last trailing twelve months KNTE reported a non-GAAP Earnings per Share(EPS) of -2.42. The EPS increased by 8.68% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -64.89% | ||
| ROE | -70.7% | ||
| Debt/Equity | 0 |
KNTE Forecast & Estimates
10 analysts have analysed KNTE and the average price target is 2.41 USD. This implies a price decrease of -9.04% is expected in the next year compared to the current price of 2.65.
KNTE Ownership
KNTE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.4 | 390.82B | ||
| AMGN | AMGEN INC | 14.96 | 176.17B | ||
| GILD | GILEAD SCIENCES INC | 15.1 | 153.42B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.88 | 113.99B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.8 | 79.49B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 716.19 | 48.25B | ||
| INSM | INSMED INC | N/A | 34.49B | ||
| NTRA | NATERA INC | N/A | 32.62B | ||
| BIIB | BIOGEN INC | 10.18 | 25.00B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 23.35B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.06 | 20.52B | ||
| INCY | INCYTE CORP | 16.62 | 20.94B |
Related stock screener links
About KNTE
Company Profile
Kinnate Biopharma, Inc. operates as a biopharmaceutical company engaged in the research and development of Kinnate Discovery Engine that targets genomic drivers of cancer. The company is headquartered in San Diego, California and currently employs 84 full-time employees. The company went IPO on 2020-12-03. The company is focused on the discovery, design and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. Its lead product candidate is exarafenib (KIN-2787), which is a Rapidly Accelerated Fibrosarcoma (RAF) inhibitor in development for the treatment of patients with lung cancer, melanoma and other solid tumors. Its second product candidate is KIN-3248, a Fibroblast Growth Factor Receptors (FGFR) inhibitor, designed for the treatment of patients with intrahepatic cholangiocarcinoma (ICC). KIN-3248 is designed to address clinically observed kinase domain mutations in FGFR2 and FGFR3. The company is also advancing other small molecule research programs, including a Cyclin-Dependent Kinase 12 (CDK12) inhibitor in its KIN004 program for the treatment of ovarian carcinoma (OC), triple-negative breast cancer (TNBC) and metastatic castration-resistant prostate cancer (mCRPC).
Company Info
KINNATE BIOPHARMA INC
11975 El Camino Real, Ste 101, Suite 101
San Diego CALIFORNIA 92130 US
CEO: Nima Farzan
Employees: 84
Phone: 18582994699
KINNATE BIOPHARMA INC / KNTE FAQ
What does KINNATE BIOPHARMA INC do?
Kinnate Biopharma, Inc. operates as a biopharmaceutical company engaged in the research and development of Kinnate Discovery Engine that targets genomic drivers of cancer. The company is headquartered in San Diego, California and currently employs 84 full-time employees. The company went IPO on 2020-12-03. The company is focused on the discovery, design and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. Its lead product candidate is exarafenib (KIN-2787), which is a Rapidly Accelerated Fibrosarcoma (RAF) inhibitor in development for the treatment of patients with lung cancer, melanoma and other solid tumors. Its second product candidate is KIN-3248, a Fibroblast Growth Factor Receptors (FGFR) inhibitor, designed for the treatment of patients with intrahepatic cholangiocarcinoma (ICC). KIN-3248 is designed to address clinically observed kinase domain mutations in FGFR2 and FGFR3. The company is also advancing other small molecule research programs, including a Cyclin-Dependent Kinase 12 (CDK12) inhibitor in its KIN004 program for the treatment of ovarian carcinoma (OC), triple-negative breast cancer (TNBC) and metastatic castration-resistant prostate cancer (mCRPC).
What is the current price of KNTE stock?
The current stock price of KNTE is 2.65 USD. The price decreased by -0.38% in the last trading session.
Does KNTE stock pay dividends?
KNTE does not pay a dividend.
What is the ChartMill technical and fundamental rating of KNTE stock?
KNTE has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the next earnings date for KNTE stock?
KINNATE BIOPHARMA INC (KNTE) will report earnings on 2024-05-09, after the market close.
What is the ownership structure of KINNATE BIOPHARMA INC (KNTE)?
You can find the ownership structure of KINNATE BIOPHARMA INC (KNTE) on the Ownership tab.